Plant alkaloid, unknown

Phase I/II


Proteosome inhibition

Phase I/II

Alternatively, the upregulation of the BCR/ABL signal through mechanisms of gene amplification may also be amenable to dose escalation. In this scenario, the intrinsic sensitivity of the cell is retained, and the desired clinical effect is a function of the dose-response curve. Critical levels of imatinib are needed to inhibit BCR/ABL function and may be achieved by increasing the doses of the agent. The experience reported by MDACC demonstrates better responses when higher doses of imatinib are used as initial therapy, and has laid the groundwork for this strategy.

0 0

Post a comment